ATHA Insider Trading
LeonaBio, Inc. | Biological Products, (No Diagnostic Substances)
Comprehensive Trading Performance Summary
The investment history of corporate insiders at LeonaBio, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2026-01-06 03:50 | 2026-01-02 | Renninger Robert | Officer - Chief Financial Officer | OPT+S | $6.88 | 297 | $2,043 | 12,857 | 0.0% |
| 2026-01-06 03:49 | 2026-01-02 | Worthington Mark | Officer - General Counsel and CCO | OPT+S | $6.88 | 876 | $6,027 | 13,978 | 0.0% |
| 2026-01-06 03:50 | 2026-01-02 | CHURCH KEVIN | Officer - CHIEF SCIENTIFIC OFFICER | OPT+S | $6.88 | 876 | $6,027 | 20,681 | 0.0% |
| 2026-01-06 03:52 | 2026-01-02 | San Martin Javier | Officer - CHIEF MEDICAL OFFICER | OPT+S | $6.88 | 1,644 | $11,311 | 10,189 | 0.0% |
| 2026-01-06 03:51 | 2026-01-02 | Litton Mark James | Director, Officer - President and CEO | OPT+S | $6.88 | 2,586 | $17,792 | 40,828 | 0.0% |
| 2025-07-02 23:35 | 2025-07-01 | CHURCH KEVIN | Officer - CHIEF SCIENTIFIC OFFICER | OPT+S | $0.29 | 8,526 | $2,502 | 168,901 | 0.0% |
| 2025-07-02 23:33 | 2025-07-01 | San Martin Javier | Officer - CHIEF MEDICAL OFFICER | OPT+S | $0.29 | 10,842 | $3,182 | 71,665 | 0.0% |
| 2025-07-02 23:33 | 2025-07-01 | Worthington Mark | Officer - General Counsel and CCO | OPT+S | $0.29 | 8,526 | $2,502 | 111,875 | 0.0% |
| 2025-07-02 23:32 | 2025-07-01 | Renninger Robert | Officer - SVP, Finance and Accounting | OPT+S | $0.29 | 2,897 | $850 | 109,186 | 0.0% |
| 2025-07-02 23:34 | 2025-07-01 | Litton Mark James | Director, Officer - President and CEO | OPT+S | $0.29 | 25,123 | $7,374 | 325,802 | 0.0% |
| 2025-01-04 01:05 | 2025-01-02 | San Martin Javier | Officer - CHIEF MEDICAL OFFICER | OPT+S | $0.56 | 10,826 | $6,083 | 35,841 | 0.0% |
| 2025-01-04 01:03 | 2025-01-02 | CHURCH KEVIN | Officer - CHIEF SCIENTIFIC OFFICER | OPT+S | $0.56 | 8,510 | $4,782 | 130,761 | 0.0% |
| 2025-01-04 01:01 | 2025-01-02 | Renninger Robert | Officer - VP of Finance | OPT+S | $0.56 | 2,881 | $1,619 | 89,724 | 0.0% |
| 2025-01-04 01:00 | 2025-01-02 | Worthington Mark | Officer - General Counsel and CCO | OPT+S | $0.56 | 8,510 | $4,782 | 83,735 | 0.0% |
| 2025-01-04 01:04 | 2025-01-02 | Litton Mark James | Director, Officer - President and CEO | OPT+S | $0.56 | 25,107 | $14,108 | 242,591 | 0.0% |
| 2024-09-06 02:50 | 2024-09-05 | Lenington Rachel | Officer - COO and CDO | SELL | $0.57 | 2,525 | $1,429 | 20,870 | -10.8% |
| 2024-09-06 02:49 | 2024-09-05 | CHURCH KEVIN | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $0.57 | 2,525 | $1,429 | 92,684 | -2.7% |
| 2024-09-06 02:48 | 2024-09-05 | Worthington Mark | Officer - GENERAL COUNSEL | SELL | $0.57 | 2,525 | $1,429 | 51,927 | -4.6% |
| 2024-09-06 02:47 | 2024-09-05 | Litton Mark James | Director, Officer - President and CEO | SELL | $0.57 | 5,032 | $2,848 | 159,365 | -3.1% |
| 2024-09-06 02:51 | 2024-09-05 | Gengos Andrew | Officer - CFO and Chief Business Officer | SELL | $0.57 | 1,272 | $720 | 97,532 | -1.3% |
| 2024-06-26 02:21 | 2024-06-21 | Romano Kelly A | Director | BUY | $2.36 | 42,400 | $100,051 | 80,715 | +110.7% |
| 2024-02-17 00:32 | 2024-01-05 | CHURCH KEVIN | Officer - CHIEF SCIENTIFIC OFFICER | SELL | $2.91 | 2,412 | $7,019 | 80,256 | -2.9% |
| 2024-02-17 00:34 | 2024-01-05 | Gengos Andrew | Officer - CFO AND CHIEF BUSINESS OFFICER | SELL | $2.91 | 1,208 | $3,515 | 83,804 | -1.4% |
| 2024-01-09 00:38 | 2024-01-05 | Worthington Mark | Officer - General Counsel | SELL | $2.91 | 2,412 | $7,019 | 34,452 | -6.5% |
| 2024-01-09 00:36 | 2023-01-05 | CHURCH KEVIN | Officer - Chief Scientific Officer | SELL | $2.91 | 2,412 | $7,019 | 80,256 | -2.9% |
| 2024-01-09 00:35 | 2024-01-05 | Lenington Rachel | Officer - Chief Operating Officer | SELL | $2.91 | 2,412 | $7,019 | 13,395 | -15.3% |
| 2024-01-09 00:40 | 2024-01-05 | Litton Mark James | Director, Officer - Chief Executive Officer | SELL | $2.91 | 4,820 | $14,026 | 144,397 | -3.2% |
| 2024-01-09 00:42 | 2023-01-05 | Gengos Andrew | Officer - See Below | SELL | $2.91 | 1,208 | $3,515 | 83,804 | -1.4% |
| 2023-12-30 01:24 | 2023-12-27 | PERCEPTIVE ADVISORS LLC | Director, 10% owner | BUY | $2.42 | 605,686 | $1,462,913 | 5,402,964 | +12.6% |
| 2023-06-10 00:06 | 2023-06-07 | Gengos Andrew | Officer - See Below | BUY | $3.43 | 15,000 | $51,446 | 80,012 | +23.1% |
| 2023-06-07 02:36 | 2023-06-02 | Gengos Andrew | Officer - See Below | BUY | $2.95 | 65,012 | $191,571 | 65,012 | +100.0% |
| 2023-03-31 23:36 | 2023-03-29 | PICKERING GRANT | Director | BUY | $2.41 | 25,000 | $60,350 | 25,783 | +3,192.8% |
| 2023-03-31 01:59 | 2023-03-29 | JOHNSON JAMES A | Director | BUY | $2.40 | 5,000 | $12,000 | 5,000 | +100.0% |
| 2022-12-31 00:58 | 2022-12-28 | MILESON GLENNA | Officer - Chief Financial Officer | BUY | $2.85 | 50,000 | $142,250 | 159,930 | +45.5% |
| 2022-12-07 04:31 | 2022-12-02 | Romano Kelly A | Director | BUY | $3.29 | 30,000 | $98,700 | 38,315 | +360.8% |
| 2022-11-18 03:10 | 2022-11-15 | MOEBIUS HANS | Officer - Chief Medical Officer | BUY | $3.29 | 5,000 | $16,442 | 65,836 | +8.2% |
| 2022-07-01 21:24 | 2022-06-29 | PERCEPTIVE ADVISORS LLC | Director, 10% owner | BUY | $2.99 | 1,371,362 | $4,100,372 | 4,797,278 | +40.0% |
| 2022-07-01 00:00 | 2022-06-28 | MOEBIUS HANS | Officer - Chief Medical Officer | BUY | $2.88 | 10,000 | $28,800 | 52,955 | +23.3% |
| 2022-06-25 02:55 | 2022-06-23 | Worthington Mark | Officer - General Counsel | SELL | $2.69 | 2,614 | $7,032 | 19,097 | -12.0% |
| 2022-06-25 02:53 | 2022-06-23 | MILESON GLENNA | Officer - Chief Financial Officer | SELL | $2.69 | 2,614 | $7,032 | 109,167 | -2.3% |
| 2022-06-25 02:50 | 2022-06-23 | Lenington Rachel | Officer - Chief Operating Officer | SELL | $2.69 | 4,193 | $11,279 | 5,807 | -41.9% |
| 2022-06-25 02:25 | 2022-06-23 | CHURCH KEVIN | Officer - Executive VP, Research | SELL | $2.69 | 2,614 | $7,032 | 57,695 | -4.3% |
| 2022-06-25 02:51 | 2022-06-23 | Litton Mark James | Director, Officer - Chief Executive Officer | SELL | $2.69 | 7,960 | $21,412 | 128,555 | -5.8% |
| 2022-04-01 23:40 | 2022-03-31 | Romano Kelly A | Director | BUY | $13.11 | 8,000 | $104,880 | 8,315 | +2,539.7% |
| 2021-01-28 01:43 | 2021-01-25 | PERCEPTIVE ADVISORS LLC | Director, 10% owner | BUY | $22.50 | 311,111 | $6,999,998 | 3,425,916 | +10.0% |
| 2020-09-23 00:03 | 2020-09-18 | RTW INVESTMENTS, LP | 10% owner | BUY | $17.00 | 750,000 | $12,750,000 | 2,668,913 | +39.1% |
| 2020-09-23 02:11 | 2020-09-22 | PERCEPTIVE ADVISORS LLC | 10% owner | BUY | $17.00 | 1,058,824 | $18,000,008 | 3,114,805 | +51.5% |
| 2020-09-23 01:03 | 2020-09-22 | EDELMAN JOSEPH | Director, 10% owner | BUY | $17.00 | 1,058,824 | $18,000,008 | 3,114,805 | +51.5% |
How to Interpret $ATHA Trades
Not every insider transaction in LeonaBio, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $ATHA shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for ATHA
Insider activity data for LeonaBio, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $ATHA, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.